

## MSCA COFUND Fellow Networking Event

4-5 March 2026

Instituto de Salud Carlos III (Monforte de Lemos, 5 Madrid)

### 4 March 2026

<b>15:00 – 15:05</b>	<b>Welcome</b> (Salon de Actos Ernest Lluch)
<b>EURAXESS Workshop</b> (Salón de Actos, Seminario, Aula,)	
<b>15:05 – 16:30</b>	<b>Interactive Workshop</b> (Elisa García, Virginia Rodríguez, Xavier Eekhout. EURAXESS Spain BHO, FECYT) <ul style="list-style-type: none"> <li>• Meet &amp; Greet</li> <li>• Career Planning</li> </ul>
<b>16:30 – 17:00</b>	<b>Coffee Break</b>
<b>Research careers in Spain</b> (Salon de Actos Ernest Lluch)	
<b>17:00 – 17:30</b>	<b>Researcher Career Path in Spain</b> (Elisa García, Virginia Rodríguez, Xavier Eekhout. EURAXESS Spain BHO, FECYT)

### 5 March 2026

<b>Plenary session on EU funding opportunities</b> (Salon de Actos Ernest Lluch)					
<b>09:30 – 10:00</b>	<b>MSCA PF keys for a successful proposal</b> (Xavier Eekhout, MSCA NCP Spain)				
<b>10:00 – 10:30</b>	<b>ERC Programme</b> (Leticia Riaza, Julio Marchamalo. ERC NCP Spain)				
<b>10:30 – 11:00</b>	<b>EIC Programme</b> (Marta Marín, EIC NCP Spain)				
<b>Plenary session on MCAA</b>					
<b>11:00 – 11:30</b>	<b>MCAA: activities and resources for fellows</b> (Joaquín Capablo. MCAA) <b>Artificial Intelligence in the preparation of proposals</b> (Ingrid Campo Ruiz, MCAA AI Working Group)				
<b>11:30 – 12:00</b>	<b>Coffee Break</b>				
<b>Fellows' Networking Sessions*</b>					
<b>12:00 – 14:00</b>	<b>LIF Panel</b> (Salon de Actos Ernest Lluch) <b>Presentation of projects and results</b>	<b>CHE Panel</b> (Seminario) <b>Presentation of projects and results</b>	<b>ENG Panel</b> (Aula) <b>Presentation of projects and results</b>	<b>PHY Panel</b> (Aula Laboratorio) <b>Presentation of projects and results</b>	<b>SOC Panel</b> (Sala de Juntas) <b>Presentation of projects and results</b>
<b>14:00 – 15:00</b>	<b>Networking Lunch</b>				
<b>15:00 – 17:00</b>	<b>LIF Panel (cont.)</b> (Salon de Actos Ernest Lluch) <b>Presentation of projects and results</b>	<b>CHE Panel (cont.)</b> (Seminario) <b>Presentation of projects and results</b>	<b>ENG Panel (cont.)</b> (Aula) <b>Presentation of projects and results</b>	<b>PHY Panel (cont.)</b> (Aula Laboratorio) <b>Presentation of projects and results</b>	<b>MSCA COFUND Programme Managers</b> (Sala de Juntas)
<b>17:00 – 17:15</b>	<b>Farewell</b>				

\* See annexes for distribution of fellows

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

## MSCA COFUND Fellow Networking Event

### 5 March 2026 Salon de Actos Ernest Lluch

Networking session in which fellows from different programmes working on research projects assigned to the panel of Life Sciences (LIF) will be able to present their projects and results to their peers. The format will be ca. 15 min presentations including questions.

#### **FELLOWS PRESENTING THEIR PROJECTS**

12:00 – 14:00

<b>Alba Timón Gómez</b>	ARISTOS	Universitat de València
<b>Aline Risson Belinovski</b>	WIT	Universidad de Navarra
<b>Giovanni Maroli</b>	Cure Heart & Brain	CNIC
<b>Irene Vázquez Domínguez</b>	ARISTOS	Hospital Ramón y Cajal. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)
<b>Javier Laura Francés</b>	Cure Heart & Brain	CNIC
<b>Patricia Morcillo</b>	ARISTOS	Universidad de Extremadura
<b>Manuel Jara Espejo</b>	AECC Talent	VHIO

15:00 – 17:00

<b>Marcos Daniel Machado Fragua</b>	Cure Heart & Brain	CNIC
<b>Marina Corrado</b>	ARISTOS	University of Barcelona
<b>Sara Lorenzoni</b>	WIT	Universidad de Navarra
<b>Jose Antonio Valverde Lopez</b>	Cure Heart & Brain	CNIC
<b>Vu Phong Dinh</b>	IDEAL PhD	IMDEA Nanociencia
<b>Sofia Romagnoli</b>	ARISTOS	CIBER

#### **PARTICIPATING FELLOWS**

Gloria de Fatima Almeida Conceição	Cure Heart & Brain	CNIC
Guiomar Masip	ARISTOS	CIBEROBN
Hana Matuskova	Cure Heart & Brain	CNIC
Inés SAENZ DE SANTA MARIA FERNANDEZ	ARISTOS	Centro de Investigación Príncipe Felipe
Rui Miguel da Costa Adão	UNA4CAREER	Universidad Complutense de Madrid

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

Joanna Kalafut	ARISTOS	Hospital del Mar Research Institute in Barcelona
Jose Garrido Mesa	AECC Talent	Fundación de Investigación Biomédica Hospital 12 de Octubre
Lilianne Beola	ARISTOS	CIBER-BBN
Lorea Jordana Urriza	WIT	CIMA Universidad de Navarra
Lucie Boulgakoff	Cure Heart & Brain	CNIC
Maelle Locatelli	ARISTOS	CIBER-IDIBAPS
Maite Sanchez-Aparicio	ARISTOS	CIBER
Marta Cimadevila	ARISTOS	CIBER
Meng	Cure Heart & Brain	CNIC
Niloufar Sadat Hosseini Giv	WIT	University of Navarra
Olalla Ramil		ARISTOS
Pablo Enrique Guevara Pantoja	ADAGIO	UPV/EHU
Seung Jae Shin	Cure Heart & Brain	CNIC
Virginia Llopis Hernández	AECC Talent	IISLaFe
Viviane de Cássia Oliveira	ARISTOS	CIBERES - Hospital Clinic Barcelona
Xiaoxi Luo	Cure Heart & Brain	CNIC

**ADDITIONAL INFORMATION:**

## Alba Timón Gómez

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** Universitat de València

**Research topic:** Development of strategies to improve the cellular uptake and endosomal escape of synthetic therapeutic oligonucleotides for rare diseases, with a proof-of-concept in myotonic dystrophy type 1

## Aline Risson Belinovski

**MSCA COFUND:** WIT

**Research Stage:** Predoctoral Researcher

**Host organisation:** Universidad de Navarra

**Research topic:** Development of cytokine-based therapies for solid tumors treatment

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

## Giovanni Maroli

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** Genetic cardiomyopathies

## Gloria de Fatima Almeida Conceição

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** Role of autophagy in postnatal cardiomyocytes and its impact on cardiac remodeling and repair. The research proposes to understand how autophagy influences cardiomyocyte fitness and contributes to maintaining heart function under stress.

## Guiomar Masip

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CIBEROBN

**Research topic:** nutritional epidemiology and omic sciences

## Hana Matuskova

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** NEUtrophil Responses in Organ-Specific STroke Outcomes and Regional Microenvironments (NEURO-STORM)

## Inés Saenz de Santa Maria Fernandez

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** Centro de Investigación Príncipe Felipe

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

**Research topic:** Inhibition of mitochondrial transfer between non-tumor and tumor cells via tunneling nanotubes using polymer nanoconjugates

## Irene Vazquez Dominguez

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** Hospital Ramón y Cajal. Instituto Ramón y Cajal de Investigación Saninataria (IRYCIS)

**Research topic:** OCU-SCAN is a research project aimed at identifying novel biomarkers for inherited retinal dystrophies by analysing extracellular vesicles from ocular samples, with the goal of improving diagnosis and founding new therapeutic venues.

## Javier Laura Francés

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** Hutchinson–Gilford progeria syndrome (HGPS) is a fatal genetic disorder caused by the expression of progerin, a mutant form of lamin A that disrupts nuclear architecture and chromatin organization. These defects drive severe cardiovascular disease (CVD), characterized by accelerated atherosclerosis, vascular smooth muscle cell (VSMC) loss, arterial stiffening, and premature death.

Although epigenetic dysregulation is increasingly recognized as a key contributor to vascular pathology during physiological aging, the epigenetic mechanisms underlying HGPS-associated CVD remain poorly defined. In particular, the role of long non-coding RNAs (lncRNAs) in mediating epigenetic dysfunction in VSMCs—the primary cellular targets of progerin toxicity—has not been investigated.

This project addresses this critical gap by examining how lncRNA-mediated epigenetic regulation contributes to VSMC dysfunction in HGPS and by evaluating lncRNA modulation as a novel therapeutic strategy. We have identified a previously uncharacterized vascular-enriched lincRNA, lncCsrp2, that is consistently upregulated in progeric VSMCs and associated with modulation of its neighboring gene, Csrp2, a key regulator of cytoskeletal organization and vascular remodeling. Functional studies demonstrate that loss of lncCsrp2 compromises VSMC viability in vitro. Together, this work establishes a mechanistic link between lncRNA dysregulation and VSMC pathology in HGPS and positions lncCsrp2 as a promising target for vascular-selective therapeutic intervention.

## Joanna Kalafut

**MSCA COFUND:** ARISTOS

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

**Research Stage:** Postdoctoral Researcher

**Host organisation:** Hospital del Mar Research Institute in Barcelona

**Research topic:** The role of Notch signaling in colorectal cancer

## Jose Antonio Valverde Lopez

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** Cardiac regeneration. Translating human pluripotent stem cell-derived cardiac therapies to improve heart failure.

## Jose Garrido Mesa

**MSCA COFUND:** AECC Talent

**Research Stage:** Postdoctoral Researcher

**Host organisation:** Fundación de Investigación Biomédica Hospital 12 de Octubre

**Research topic:** Development and validation of bispecific antibody therapies for SCLC

## Lilianne Beola

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CIBER-BBN

**Research topic:** Bio Nanomedicine Applied to brain tumor anticancer research

## Lorea Jordana Urriza

**MSCA COFUND:** WIT

**Research Stage:** Predoctoral Researcher

**Host organisation:** CIMA Universidad de Navarra

**Research topic:** scRNA-seq analysis of CAR T cells against Multiple Myeloma

## Lucie Boulgakoff

**MSCA COFUND:** Cure Heart & Brain

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** The aim of this project is to identify regulatory signals that enhance lymphangiogenesis, and to use them to improve cardiac recovery after a myocardial infarction

## Maelle Locatelli

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CIBER-IDIBAPS

**Research topic:** My project explores how HBV evades immune control and establishes chronic infection. I will study viral escape during liver transplantation and use single-cell RNA sequencing to define immune cell signatures in HBeAg-negative chronic hepatitis B, aiming to identify predictors of treatment outcome after nucleos(t)ide analogue therapy.

## Maite Sanchez-Aparicio

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CIBER

**Research topic:** Infectious disease research

## Manuel Jara Espejo

**MSCA COFUND:** AECC Talent

**Research Stage:** Postdoctoral Researcher

**Host organisation:** VHIO

**Research topic:** Currently I am investigating how malignant cells exploit their ability to get access to multiple functional programs, a process called transcriptional plasticity, in early- and late-stage tumors. We want to know which programs exist, how they are used across cancer types and how their activity is related to the genomic profile of the patients.

## Marcos Daniel Machado Fragua

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

**Research topic:** Alternative measures of adiposity to define obesity and risk of dementia

## Marina Corrado

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** University of Barcelona

**Research topic:** Glycaemic impact of phenolic compounds

## Marta Cimadevila

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CIBER

**Research topic:** MYELINPLUS aims to boost central nervous system myelination through activation of G protein-coupled receptors (GPCRs) in oligodendrocytes

## Meng Zhang

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** Mechanisms and therapies to promote endothelial protection against reperfusion injury

## Niloufar Sadat Hosseini Giv

**MSCA COFUND:** WIT

**Research Stage:** Predoctoral Researcher

**Host organisation:** University of Navarra

**Research topic:** Ovarian cancer is the most lethal gynaecological malignancy, with many cases diagnosed at advanced stages due to a lack of specific symptoms. The first-line treatment includes surgery along with chemotherapy, but relapse and chemotherapy resistance are common challenges. Many studies have proved that therapy-induced senescence (TIS) triggered by platinum drugs contributes to treatment failure, relapse, and metastasis by promoting a pro-tumour microenvironment through the senescence-associated secretory phenotype (SASP). Since a small number of the cells undergo cell cycle arrest and become senescent, and due to the lack of a specific marker for this cell population, finding markers

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

seems to be crucial in cancer treatment. Here, we will investigate long noncoding RNAs (lncRNAs) as a novel marker for senescence and a potential target for developing new therapeutic approaches.

## Olalla Ramil

**MSCA COFUND:**

**Research Stage:** Postdoctoral Researcher

**Host organisation:** ARISTOS

**Research topic:** Cardiovascular disease is the leading cause of death in peritoneal dialysis (PD) patients. This renal replacement therapy uses the peritoneum as a natural semipermeable filter to remove the toxins and the excess of water that the kidneys are unable to eliminate. These waste products are transferred from the bloodstream into a dialysis fluid instilled in the peritoneal cavity of the patient, which is subsequently drained and discarded. While PD is a life-sustaining treatment, continuous exposure to non-physiological dialysis fluids induces a chronic inflammatory response in the peritoneum which may progress to fibrosis, angiogenesis, and ultimately ultrafiltration failure. Previous studies recognized inflammation as a non-traditional cardiovascular risk factor in PD patients; however, the potential contribution of peritoneal damage itself to cardiovascular injury remains largely unexplored.

This project hypothesizes that peritoneal fibrosis is not only a complication of PD, but also a driver of systemic inflammation and cardiovascular damage in these patients. Therefore, this study aims to assess the impact of peritoneal injury on cardiovascular damage in PD patients through a multilayered analysis. To address this, we will characterize a molecular signature of peritoneal injury by integrating inflammatory and profibrotic mediators and investigate their association with cardiovascular damage markers and clinical outcomes using in vitro, ex vivo, and in vivo approaches. Additionally, we will evaluate the potential protective effect of a healthy diet in preserving peritoneal membrane integrity and preventing cardiovascular damage. By bridging peritoneal pathology and cardiovascular outcomes, this study could identify novel cardiovascular damage biomarkers and open new therapeutic avenues to improve cardiovascular injury in PD patients.

## Pablo Enrique Guevara Pantoja

**MSCA COFUND:** ADAGIO

**Research Stage:** Postdoctoral Researcher

**Host organisation:** UPV/EHU

**Research topic:** Biomedical devices and microfluidics

## Patricia Morcillo

**MSCA COFUND:** ARISTOS

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

**Research Stage:** Postdoctoral Researcher

**Host organisation:** Universidad de Extremadura

**Research topic:** The project AGELESS examines whether restoring normal mitochondrial dynamics can improve neuronal resistance to age-related deterioration. The goal of this work is to advance our understanding of neuronal vitality and longevity research, ultimately contributing to the development of future therapies that prolong life expectancy.

## Rui Miguel da Costa Adão

**MSCA COFUND:** UNA4CAREER

**Research Stage:** Postdoctoral Researcher

**Host organisation:** Universidad Complutense de Madrid

**Research topic:** The project was designed to advance the understanding of potassium ( $K^+$ ) channel dysregulation in pulmonary arterial hypertension (PAH) and to explore the therapeutic potential of targeting these channels.

## Sara Lorenzoni

**MSCA COFUND:** WIT

**Research Stage:** Predoctoral Researcher

**Host organisation:** Universidad de Navarra

**Research topic:** This research focuses on the development of targeted nanomedicine strategies for the treatment of high-risk neuroblastoma. Specifically, it investigates integrin-targeted solid lipid nanoparticles functionalized with cyclic RGD peptides to improve the selective delivery and therapeutic efficacy of etoposide. The project combines nanoparticle design, physicochemical characterization, and advanced biological validation in both 2D cell cultures and biomimetic 3D neuroblastoma tumoroid models. By enhancing tumor-specific uptake and antitumor activity while reducing off-target effects, the work aims to advance translational nanomedicine approaches for more precise and effective pediatric cancer therapies.

## Seung Jae Shin

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** I am working in Miguel Angel's (<https://www.cnic.es/es/miguel-angel-pozo-barriuso>), Caveolae mechanoadaptation Lab, researching about how mechanical stress modulate monocyte/macrophage mechanotransduction, leading to atherosclerosis

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

progression or regression. Although it is known that mechanical stress and monocyte/macrophage activation are key risk factors for the disease progression, the underlying mechanism how these modulate atherosclerosis development is not understood well. So, my research aims to unravel the association between mechanical stress and atherosclerosis, mainly targeting monocyte/macrophage.

## Sofia Romagnoli

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CIBER

**Research topic:** Combined use of noninvasive ECGi and multiscale cardiac models to improve risk stratification in Brugada Syndrome

## Virginia Llopis Hernández

**MSCA COFUND:** AECC Talent

**Research Stage:** Postdoctoral Researcher

**Host organisation:** IISLaFe

**Research topic:** Influence of microbiome in cancer progression

## Viviane de Cássia Oliveira

**MSCA COFUND:** ARISTOS

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CIBERES - Hospital Clinic Barcelona

**Research topic:** The use of a new therapeutic approach to controlling infections, especially those caused by multidrug-resistant pathogens.

## Vu Phong Dinh

**MSCA COFUND:** IDEAL PhD

**Research Stage:** Predoctoral Researcher

**Host organisation:** IMDEA Nanociencia

**Research topic:** Nucleic acid based therapy for Duchenne muscular dystrophin



Xiaoxi Luo

**MSCA COFUND:** Cure Heart & Brain

**Research Stage:** Postdoctoral Researcher

**Host organisation:** CNIC

**Research topic:** Essential interplay between the placenta and the heart during cardiovascular development and its implications for congenital heart disease